慢性阻塞性肺疾病患者血清和痰液中表面活性蛋白D的水平及临床意义

目的:探讨慢性阻塞性肺疾病(chronic obstructive pulmonary disease,AECOPD)患者血清和痰液中表面活性蛋白D(surfactant protein D,SP-D)的水平和临床意义。方法:选取急性加重期COPD(acute exacerbation of COPD,AECOPD)患者34例(A组)、稳定期COPD患者37例(B组)、有嗜烟史的健康人30例(C组)、无嗜烟史的健康人30例(D组)。分别检测4组血清和痰液中的SP-D水平,并分析AECOPD患者血清和痰液SP-D水平的相关性。结果:A、B、C、D组的血清SP-D水平依次为(165.09±16.72)、(126.48±15.64)、(72.85±8.62)、(54.70±7.29)ng/mL,痰液SP-D水平依次为(109.03±18.95)、(133.28±16.36)、(260.04±47.91)、(665.89±117.49)ng/mL;血清和痰液SP-D水平在4组间的差异均有统计学意义(P0.05)。AECOPD患者的血清SP-D水平和痰液SP-D水平呈负相关(r=-0.698,P0.05)。结论:AECOPD患者的血清、痰液SP-D水平呈负相关。血清、痰液SP-D水平的监测有助于临床AECOPD病情的评估。     

支气管肺发育不良患儿血清骨膜蛋白、表面活性蛋白D水平变化及意义

目的 探讨支气管肺发育不良（bronchopulmonary dysplasia,BPD）患儿血清骨膜蛋白（periostin,POSTN）、表面活性蛋白D(surfactant protein D,SP-D)水平变化及意义。方法 回顾性选取2021年1月至2022年12月海南省东方市人民医院收治早产儿178例为研究对象,根据是否发生BPD分为BPD组（46例）和非BPD组（132例）,根据病情将BPD患儿分为轻度组（17例）、中度组（20例）和重度组（9例）。检测各组患儿出生后第1天和第14天时血清POSTN、SP-D水平,分析POSTN、SP-D对早产儿BPD的诊断价值。结果 BPD组出生后第1天和第14天时血清POSTN、SP-D水平明显高于非BPD组（P<0.05）,且重度组患儿血清POSTN、SP-D水平高于中度组和轻度组,中度组又高于轻度组（P<0.05）。出生后第1天血清POSTN、SP-D诊断早产儿BPD的曲线下面积为0.740、0.747,出生后第14天血清POSTN、SP-D诊断早产儿BPD的受试者工作特征曲线下面积为0.877、0.888。结论 BPD...     

肺纤维化大鼠血清克拉拉细胞蛋白和表面活性蛋白-D动态变化及早期诊断意义

目的 探讨克拉拉细胞蛋白(CC16)和表面活性蛋白-D(SP-D)在肺纤维化大鼠中的表达水平及早期诊断意义.方法 Wistar大鼠60只随机分为正常对照组(对照组)、博莱霉素致肺纤维化组(模型组).每组30只,分别于造模后1、3、7、14、28 d处死,采用HE、Masson染色观察其肺组织病理变化,碱水解法测定肺组织羟脯氨酸含量,酶联免疫吸附法测定血清CC16、SP-D水平.结果 模型组大鼠肺组织羟脯氨酸含量自第7天[(913.1±69.3)μg/g]起,较对照组[(790.5±36.8)μg/g]升高(P<0.05);血清CC16自第3天[(27.34±0.32)μg/L]开始,低于对照组[(27.85 ±0.32)μg/L](P<0.05),并随病情进展而逐渐降低;血清SP-D各时相均高于对照组(P均<0.05),并且随病情进展而逐渐升高.结论 血清CC16、SP-D在大鼠肺纤维化早期有明显改变,其水平变化可能为肺纤维化的早期诊断提供生物学指标.     

肺纤维化大鼠血清克拉拉细胞蛋白和表面活性蛋白-D动态变化及早期诊断意义

Objective To detect the dynamic changes of the level of serum Clara cell protein(CC16)and surfactant protein-D(SP-D)in rats with pulmonary fibrosis induced by bleomycin and to evaluate their value in early diagnosis of pulmonary fibrosis. Methods Sixty Wistar rats were randomly divided into two groups, the control group and bleocin-induced pulmonary fibrotic group,with 30 rats in each group. The rats were killed at 1,3,7,14 and 28 days of treatment Pathology changes of lung tissue were observed by HE,Masson stain,alkaline hydrolysis to assess the hydroxyproline concentration of lung tissue, enzyme-linked immunosorbent assay (ELISA) was used to measure the levels of serum CC16 and SP-D. Results The hydroxyproline concentration of lung tissue in the pulmonary fibrotic group ((913. 1 ±69. 3) μg/g) were higher than those of the control group ((790. 5 ± 36. 8) μg/g) from the seventh day(P <0. 05). The levels of serum CC16 of the pulmonary fibrotic group((27. 34 ± 0. 32) μg/L) were lower than those of the control group((27. 85 ±0. 32)μg/L) since the third day(P<0. 05) ,and tended to decrease with the development of the disease. However,the levels of SP-D of the former group were always higher(P <0. 05), and tended to increase with the development of the disease. Conclusions The levels of serum CC16 and SP-D changed considerably in early-stage of pulmonary fibrosis, thus might be used as biomarker for early diagnosis and have some value for pathogenesis of pulmonary fibrosis.     

肺纤维化大鼠血清克拉拉细胞蛋白和表面活性蛋白-D动态变化及早期诊断意义

Objective To detect the dynamic changes of the level of serum Clara cell protein(CC16)and surfactant protein-D(SP-D)in rats with pulmonary fibrosis induced by bleomycin and to evaluate their value in early diagnosis of pulmonary fibrosis. Methods Sixty Wistar rats were randomly divided into two groups, the control group and bleocin-induced pulmonary fibrotic group,with 30 rats in each group. The rats were killed at 1,3,7,14 and 28 days of treatment Pathology changes of lung tissue were observed by HE,Masson stain,alkaline hydrolysis to assess the hydroxyproline concentration of lung tissue, enzyme-linked immunosorbent assay (ELISA) was used to measure the levels of serum CC16 and SP-D. Results The hydroxyproline concentration of lung tissue in the pulmonary fibrotic group ((913. 1 ±69. 3) μg/g) were higher than those of the control group ((790. 5 ± 36. 8) μg/g) from the seventh day(P <0. 05). The levels of serum CC16 of the pulmonary fibrotic group((27. 34 ± 0. 32) μg/L) were lower than those of the control group((27. 85 ±0. 32)μg/L) since the third day(P<0. 05) ,and tended to decrease with the development of the disease. However,the levels of SP-D of the former group were always higher(P <0. 05), and tended to increase with the development of the disease. Conclusions The levels of serum CC16 and SP-D changed considerably in early-stage of pulmonary fibrosis, thus might be used as biomarker for early diagnosis and have some value for pathogenesis of pulmonary fibrosis.     

肺表面活性蛋白A与急性肺损伤

肺表面活性蛋白(Surfactant Protem,SP)是70年代末才被认识的一类特异性综合蛋白,主要由肺泡Ⅱ型上皮细胞(AT-Ⅱ)和细支气管非纤毛上皮细胞(Clara 细胞)分泌,占肺表面活性物质(Pulmonary Surfactant,PS)的10％左右。目前分离出的SP包括亲水性的SP-A、SP-D和疏水性的SP-B、SP-C。其中SP-A是最早被发现且在AT-Ⅱ中表达最强烈,信号最丰富的蛋白,是PS中最重要的蛋白成分,其功能及生     

特发性肺纤维化患者血清淀粉样蛋白A和钙卫蛋白水平变化及临床意义研究

目的 探讨血清淀粉样蛋白A(SAA)和钙卫蛋白水平变化与特发性肺纤维化(IPF)的关系.方法 收集2016-2019年该院的IPF患者25例为IPF组,同时收集肺部其他疾病患者25例为疾病对照组和纤维支气管镜、影像学检查正常者25例为健康对照组.测定所有研究对象血清SAA和钙卫蛋白水平并进行比较,分析二者与肺功能指标的...     

慢性阻塞性肺疾病急性加重期患者中诱导痰炎性标志物的变化临床观察

将2012年的4月~2014年的7月在我院呼吸内科住院的412名中度、重度AECOPD患者作为此次研究的观察对象,所有患者行诱导痰检查后,将诱导痰EOS%≥3%且给予基础治疗加用甲泼尼龙的79例患者分为A组,EOS%≥3%给予单纯给予基础治疗的108例分为B组,EOS%≤3%且给予基础治疗加用甲泼尼龙的116例分为C组,EOS%≤3%且单纯给予基础治疗的109例分为D组。四组患者分别在入院第1d及第14d记录患者的诱导痰EOS%,CAT评分、PaO_2/FiO_2、CRP水平的变化。结果 A组较B组在治疗后EOS%显著下降,CAT评分显著改善,PaO_2、PaO_2/FiO_2显著好转;A组较C组在治疗后EOS%显著下降,CAT评分显著改善,PaO_2、PaO_2/FiO_2显著好转;C组与D组在治疗后EOS%、CAT评分、Pa O_2、PaO_2/FiO_2均无明显差异。急性加重期慢性阻塞性肺病患者的气道同时具有中性粒细胞炎症和嗜酸性粒细胞炎症的特征,诱导痰E0S%指数可作为检测慢性阻塞性肺病急性加重期的指标。     

脓毒症所致ARDS患者血浆肺表面活性蛋白D水平及其临床意义

目的探讨脓毒症所致急性呼吸窘迫综合征（ARDS）患者血浆肺表面活性蛋白-D（SP—D）水平动态变化的临床意义及其与临床特征的相关性。方法前瞻性研究脓毒症患者不同病程阶段血浆样本,于2012年1月至2012年10月入住重症医学科的40例患者纳入研究。根据收集血浆时患者是否符合ARDS诊断分为系统性炎症反应综合征（SIRS）组（即对照组）与ARDS组。ARDS组根据柏林ARDS诊断标准分为轻度、中度、重度3个亚组,ARDS重度患者临终前再次采集血浆样本,纳入ARDS临终组,运用酶联免疫吸附法测定各组血浆样本的SP—D水平,再结合患者的临床特征进行相关分析。结果ARDS轻度组的SP—D的血浆水平高于SIRS组（0．723±0．153rig／ml比0．510±0．187ng／ml,P〈0．05）;随着ARDS病情加重,血浆SP—D水平呈进行性升高（ARDS轻度组比中度组0．723±0．153．g／ml比1．043±0．198ng／ml,P〈0．05;中度组比重度组：1．043±0．198ng／ml比1．343±0．186ng／ml。P〈0．05）。临终组较ARDS重度组,SP—D水平无显著差异（1．343±0．186ng／ml比1．398±0．216ng／ml,P〉0．05）。血浆SP—D水平Pa02／FiO2呈负相关（r值为-0．436,P〈0．05）,与AaDO2、SOFA评分和APACHEII评分呈正相关（r值分别为0．314、0．321和0．453,P〈0．05）。结论检测脓毒症患者血浆SP—D水平有助于脓毒症所致ARDS的早期诊断。     

慢性阻塞性肺疾病患者血清CC16及SP—D水平变化及意义

目的观察慢性阻塞性肺疾病（chronicobstructivepulmonarydisease,COPD）患者血清人克拉拉细胞蛋白（Claracellprotein,CCl6）及肺表面活性物质相关蛋白D（surfactantassociatedproteinD,SP—D）水平变化及其临床意义。方法检测33例COPD患者急性加重期及经正规治疗后进入稳定期时CCl6与SP—D水平,及稳定期第1秒用力呼气容积（forcedexpiratoryvolumeinonesecond,FEVl）占预计值百分比（FEVl％）、FEVl／用力肺活量（forcedvitalcapacity,FVC）、肺一氧化碳弥散量（carbonmonoxidediffusingcapacityofthelung,DLC0）占预计值百分比（DLCO％）,并与2l例体检健康者（对照组）检测结果进行对照,分析CCl6及SP—D与肺功能FEV,％及DLCO％间的相关性。结果COPD患者加重期、稳定期及对照组血清CCl6分别为（65．93±29．79）、（93．45±42．65）、（118．93±49．29）μg／L,SPD分别为（154．41土46．23）、（125．20±40．41）、（90．07±30．82）μg／L,两两比较差异均有统计学意义（P〈0．01）;COPD患者稳定期FEVl％、FVC、FEVl／FVC、DLCO％均低于对照组（P〈0．05）;稳定期血清CCl6与FEVl％呈正相关（r=0．568,P〈0．01）,血清SP—D水平与DLCO％呈负相关（r=-0．638,P％0．01）,与FEVl％呈负相关（r=-0．609,P〈0．01）。结论血清CCl6及SP—D可能成为COPD诊断、分期的生物学标志物。     

Increased serum levels of endostatin in patients with idiopathic pulmonary fibrosis

Endostatin is an angiogenesis inhibitor that is an endogenously produced proteolytic fragment of type XVIII collagen. Serum levels of endostatin have been studied extensively in patients with malignant diseases. Recently, elevated serum endostatin levels were observed in patients with systemic sclerosis accompanying pulmonary fibrosis. To determine whether elevated serum endostatin can be observed in patients with idiopathic pulmonary fibrosis (IPF), we measured serum levels of endostatin in 69 patients with benign respiratory disease using an ELISA kit. The median of the serum endostatin levels in these patients was 50.8 pg/mL. Seven of 11 patients (63.6%) with collagen disease-associated pulmonary fibrosis (CDPF), and 19 of 24 patients (79.2%) with IPF had higher serum endostatin levels than the median level of the 69 patients. There was no statistical difference in serum endostatin levels between the patients with IPF and those with CDPF (P=0.7898). Serum endostatin levels in 24 patients with IPF were significantly higher than those in 34 patients with respiratory diseases other than IPF and CDPF (P=0.0001). Elevated serum levels of endostatin were observed in patients with IPF. Although the mechanisms are unclear, elevated serum levels of endostatin may be related to the fibrosing process in the lung.     

慢性阻塞性肺疾病患者诱导痰液中IL-6和IL-8水平变化的临床意义

目的探讨慢性阻塞性肺疾病(COPD)患者诱导痰液中白细胞介素-6(IL-6)和白细胞介素-8(IL-8)水平变化的临床意义。方法选取COPD患者35例为COPD组,另选取健康体检者40例为健康组,根据有无吸烟史分为无吸烟22例和吸烟18例。2组受试者行肺功能检测,运用诱导痰液方法收集痰液,酶联免疫吸附试验(ELISA)测定痰液上清中IL-6和IL-8水平变化,Spearman相关性检验分析IL-6、IL-8水平与肺功能的相关性。结果 COPD组诱导痰液中性粒细胞百分比显著高于健康组无吸烟者和吸烟者(P0.05或P0.01);痰上清中IL-6、IL-8水平显著高于健康组无吸烟者和吸烟者(P0.05)。相关性分析显示,COPD组诱导痰上清IL-6与第1秒用力呼气容积占预期值百分比(FEV1%)和第1秒用力呼气容积占用力肺活量的百分比(FEV1/FVC)呈负相关(P0.01),IL-8与FEV1%和FEV1/FVC呈负相关(P0.01)。结论 COPD患者气道腔内存在以中性粒细胞浸润为主的慢性气道炎症,IL-6和IL-8可能在气道损伤和重塑过程中扮演重要作用。     

Acute exacerbation of idiopathic pulmonary fibrosis model by small amount of lipopolysaccharide in rats

Idiopathic pulmonary fibrosis, a chronic and progressive lung disease with poor prognosis, presents with acute exacerbation. Pathophysiology and treatments for this acute exacerbation, and an appropriate animal model to perform such examinations, have not established yet. We presented a rat model for assessing acute exacerbation in cases of idiopathic pulmonary fibrosis. Wistar rats were intratracheally administered bleomycin (3 mg/kg) to induce pulmonary fibrosis. After 7 days, lipopolysaccharide (0, 0.05, or 0.15 mg/kg) was administered. In the bleomycin or lipopolysaccharide group, there were almost no change in the oxygen partial pressure, arterial blood gas (PaO₂), plasma nitrite/nitrate, nitric oxide synthase, and lung nitrotyrosine levels. In the bleomycin (+)/lipopolysaccharide (+) groups, these three indicators deteriorated significantly. The plasma nitrite/nitrate and PaO₂ levels were significantly correlated in the bleomycin (+) groups (r = 0.758). Although lung fibrosis was not different with or without lipopolysaccharide in the bleomycin (+) groups, macrophage infiltration was marked in the bleomycin (+)/lipopolysaccharide (+) group. There were many NOS2-positive macrophages, and the PaO₂ levels decrease may be induced by the nitric oxide production of macrophages in the lung. This model may mimic the pathophysiological changes in cases of acute exacerbation during idiopathic pulmonary fibrosis in humans.     

慢性阻塞性肺疾病患者诱导痰上清液及血清中基质金属蛋白酶的表达

目的检测慢性阻塞性肺疾病（COPD）不同时期患者诱导痰上清液及血清中基质金属蛋白酶9（MMP-9）、基质金属蛋白酶组织抑制剂1（TI MP-1）浓度,分析其与COPD病情变化的关系。方法选择COPD缓解期组、COPD急性加重期（AECOPD）组和正常对照组各20例,采用双抗夹心酶联免疫吸附测定法检测各组受试者诱导痰上清液及血清中MMP-9、TI MP-1的浓度。结果AECOPD组和COPD缓解期组诱导痰上清液及血清MMP-9浓度均高于正常对照组,诱导痰上清液MMP-9（612.2±58.9）μg/L、（401.5±45.7）μg/L vs（186.2±77.4）μg/L（P〈0.01）,血清MMP-9（221.7±30.4）μg/L、（203.0±33.5）μg/Lvs（131.4±44.5）μg/L（P〈0.01）;AECOPD组诱导痰上清液及血清MMP-9浓度均高于COPD缓解期组（P〈0.01）。AECOPD组和COPD缓解期组诱导痰上清液及血清TI MP-1浓度均高于正常对照组,诱导痰上清液TI MP-1（859.3±101.0）μg/L、（356.4±92.1）μg/L vs（97.1±54.2）μg/L（P〈0.01）,血清TI MP-1（213.2±27.2）μg/L、（149.9±20.1）μg/L vs（84.1±14.0）μg/L（P〈0.01）;AECOPD组血清TI MP-1浓度均高于COPD缓解期组（P〈0.01）。AECOPD组和COPD缓解期组诱导痰上清液及血清MMP-9/TI MP-1比值均低于正常对照组（P〈0.01）;AECOPD组血清MMP-9/TI MP-1比值低于COPD缓解期组（P〈0.01）。结论COPD不同时期诱导痰及血清中MMP-9、TI MP-1含量不同,提示存在蛋白酶/抗蛋白酶失衡机制。     

慢性阻塞性肺疾病急性加重期血清CRP与动脉血气联合检测的临床意义

目的探讨慢性阻塞性肺疾病急性加重期血清CRP与动脉血气联合检测的临床意义。方法选取2008年12月～2010年1月于我院进行治疗的30例慢性阻塞性肺疾病患者为观察组,选取同期的30名健康人员为对照组,后将观察组急性加重期及缓解期和对照组的血清CRP与动脉血气进行检测及比较。结果经研究比较发现,观察组的急性加重期及缓解期血清CRP明显高于对照组,PaCO2高于对照组,PaO2低于对照组,SaO2低于对照组,HCO3-水平高于对照组,P〈0．01或P〈0．05,有非常显著性差异。结论血清CRP与动脉血气联合检测在慢性阻塞性肺疾病急性加重期有着重要的意义．可以准确了解患者的疾病严章程度以为治疗提供治疗依据。     

慢性阻塞性肺病急性加重患者前白蛋白及C反应蛋白变化及临床意义

目的探讨慢性阻塞性肺病（COPD）急性加重患者治疗前后血前白蛋白（PA）、C反应蛋白（CRP）的变化及临床意义。方法选择COPD急性加重住院患者78例,分别测定入院时及病情缓解后稳定期的血PA和CRP,并与健康对照组比较。结果 COPD患者急性加重期较稳定期PA明显下降,并且均较对照组明显降低,CRP明显升高,差异有统计学意义。结论血清PA、CRP可作为评估COPD患者急性加重期病情控制的指标。     

慢性阻塞性肺疾病患者急性加重期血清降钙素原水平变化及其临床意义

目的探讨慢性阻塞性肺疾病(COPD)患者急性加重期血清降钙素原(PCT)水平变化及其临床意义。方法选择COPD急性加重期患者103例,按治疗前痰中病原菌浓度分为感染组59例和未感染组44例。观察治疗前后血清PCT水平,并分析其与预后的关系。结果治疗前感染组血清PCT水平显著高于未感染组(P<0.01),治疗后显著降低(P<0.01),与未感染组相比差异无统计学意义(P>0.05)。随着PCT水平增加,感染组患者使用抗生素治疗时间及住院时间越长(P<0.05,P<0.01),死亡率越高(P>0.05)。结论 COPD急性加重期患者血清PCT水平升高提示可能存在细菌感染,PCT含量可作为辅助诊断、预后评估的工具。     

急性肺损伤患者血清肺表面活性物质蛋白A的变化及其意义

目的;动态观测急性肺损伤虱血清肺表面活性物质蛋白Ａ（ＳＰ－Ａ）的变化,并探讨其临床意义。方法：选择符合ＡＬＩ诊断标准并已给予机械通气治疗的患者２０例,于入组时和出组时抽取静脉血,多数患者在观察期间病情有明显变化时重复抽血,共收集静脉血标本７１例次;并同时记录动脉血气测值和呼吸机参数,计算动脉血氧分压与吸入气氧浓度比值和静态总呼吸顺应性。     

特发性肺纤维化患者血清基质金属蛋白酶-9水平及其临床意义

目的探讨血清基质金属蛋白酶9水平对特发性肺纤维化患者早期诊断的价值。方法采用酶联免疫吸附法对32例特发性肺纤维化患者(早期组19例,非早期组13例)和24例健康人(健康对照组)血清基质金属蛋白酶9进行测定。结果早期组和非早期组血清基质金属蛋白酶9均高于健康对照组,差异有显著性意义(P<0.01);早期组血清基质金属蛋白酶9高于非早期组,两组间比较差异有显著性意义(P<0.01)。结论基质金属蛋白酶9在特发性肺纤维化发病机制中起着重要作用,血清基质金属蛋白酶9测定对特发性肺纤维化早期诊断具有一定价值。     

特发性肺纤维化患者血清肿瘤标志物含量变化及其临床意义

目的 探讨特发性肺纤维化(IPF)患者血清多种肿瘤标志物含量的变化及其临床意义.方法 采用化学发光法检测25例IPF患者(IPF组)和23例正常对照者(对照组)外周血多种肿瘤标志物甲胎蛋白(AFP)、癌胚抗原(CEA)、CA125、CA153、CA199,同时检测患者血气、肺功能参数等临床指标.结果 IPF组与对照组外周血AFP[(2.41±0.95)μg/L与(1.29±1.13)μg/L,t=4.32,P＜0.05]、CEA[(7.12±2.68)μg/L与(2.14±0.57)μg/L,t=3.69,P＜0.05]、CA125[(118.52±31.24)kU/L与(23.97±8.47)kU/L,t=4.15,P＜0.05]、CA153[(47.58±14.57)kU/L与(9.24±4.21)kU/L,t=5.87,P＜0.05]、CA199[(165.78±21.13)kU/L与(14.51±5.74)kU/L,t=4.22,P＜0.05]均明显高于对照组,差异具有统计学意义.且血清AFP、CEA、CA125、CA153、CA199含量均与动脉血氧分压(r值为-0.15～-0.55,P＜0.05)、肺活量(r值为-0.09～-0.49,P＜0.05或P＜0.01)、肺弥散量(r值为-0.17～-0.61,P＜0.05)呈负相关.各肿瘤标志物与ESR和CRP无相关性(P均＞0.05).血清多种肿瘤标志物的进行性升高与肺纤维化程度的进展正相关.经激素治疗后,25例IPF患者血清AFP[(2.41±0.95)μg/L与(1.67±1.22)μg/L,t=5.41,P＜0.05]、CEA[(7.12±2.68)μg/L与(3.75±1.96)μg/L,t=4.63,P＜0.05]、CA125[(118.52±31.24)kU/L与(53.22±13.56)kU/L,t=3.97,P＜0.05]、CA153[(47.58±14.57)kU/L与(19.35±8.74)kU/L,t=5.15,P＜0.05]、CA199[(165.78±21.13)kU/L与(58.85±17.31)kU/L,t=6.34,P＜0.05]水平明显下降.结论 IPF患者血清多种肿瘤标志物含量增加,并与肺功能损害程度密切相关,可能提示肺纤维化的进展,是预后不良的标志.

Abstract：

Objective To investigate the clinical significance of multi-tumor biomarkers combined variation in patients with idiopathic pulmonary fibrosis(IPF).Methods Multiple serum tumor biomarkers,including AFP,CEA,CA125,CA153 and CA199 were detected in 25 patients with IPF and 23 healthy controls by chemiluminescence method,and the blood gas analysis,pulmonary function parameters and other clinical data were also collected simultaneously.Results All serum biomarkers measured in this study were significantly higher in IPF group than control,AFP([2.41±0.95]μg/L vs.[1.29±0.13]μg/L,t=4.32,P＜0.05),CEA([7.12±2.68]μg/L vs.[2.14±0.57]μg/L,t=3.69,P＜0.05),CA125([118.52±31.64]kU/L vs.[23.97±8.47]kU/L,t=4.15,P＜0.05),CA153([47.58±14.57]kU/L vs.[9.24±4.21]kU/L,t=5.87,P＜0.05),and CA199([165.78±21.13]kU/L vs.[14.51±5.74]kU/L,t=4.22,P＜0.05).The serum levels of AFP,CEA,CA125,CA153,CA199 were negatively correlated with blood oxygen pressure(r=-0.15--0.55,Ps＜0.05),vital capacity(r=-0.09--0.49,Ps＜0.05),lung diffusion capacity(r=-0.17--0.61,Ps＜0.05),while no significant correlations were found between different biomarker levels and ESR and CRP(Ps＞ 0.05).In addition,the serum level of different tumor markers increased along with the progress of pulmonary fibrosis,which showed statistical significance(Ps＜0.05).After hormone medication therapy,the serum tumor marker levels decreased significantly in IPF patients[AFP[2.41±0.95]μg/L vs.[1.67±1.22]μg/L,t=5.41,P＜0.05,CEA([7.12±2.68]μg/L vs.[3.75±1.96]μg/L,t=4.63,P＜0.05,CA125([118.52±31.64]kU/L vs.[53.22±13.56]kU/L,t=3.97,P＜0.05),CA153(47.58±14.5 vs.19.35±8.74 kU/L,t=5.15,P＜0.05),CA199(165.78±21.13 vs.58.85±17.31 kU/L,t=6.34,P＜0.05)].Conclusion Multiple serum tumor biomarkers significantly increased in patients with IPF,and had a close correlation with lung function damage.The changes of these biomarkers indicated the progress of pulmonary fibrosis,which served as the predictors of poor prognosis.